LYRA Valuation
Lyra Therapeutics Inc
$
7.400
- Overview
- Forecast
- Valuation
- Earnings
LYRA Relative Valuation
LYRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LYRA is overvalued; if below, it's undervalued.
Historical Valuation
Lyra Therapeutics Inc (LYRA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 11.18 is considered Undervalued compared with the five-year average of -2.47. The fair price of Lyra Therapeutics Inc (LYRA) is between 7.31 to 29.31 according to relative valuation methord. Compared to the current price of 6.60 USD , Lyra Therapeutics Inc is Undervalued By 9.74%.
Relative Value
Fair Zone
7.31-29.31
Current Price：6.60
9.74%
Undervalued
-0.23
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Lyra Therapeutics Inc. (LYRA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.21. The thresholds are as follows: Strongly Undervalued below -4.19, Undervalued between -4.19 and -2.70, Fairly Valued between 0.28 and -2.70, Overvalued between 0.28 and 1.77, and Strongly Overvalued above 1.77. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.29
EV/EBIT
Lyra Therapeutics Inc. (LYRA) has a current EV/EBIT of -0.29. The 5-year average EV/EBIT is -0.93. The thresholds are as follows: Strongly Undervalued below -3.22, Undervalued between -3.22 and -2.07, Fairly Valued between 0.21 and -2.07, Overvalued between 0.21 and 1.36, and Strongly Overvalued above 1.36. The current Forward EV/EBIT of -0.29 falls within the Historic Trend Line -Fairly Valued range.
11.13
PS
Lyra Therapeutics Inc. (LYRA) has a current PS of 11.13. The 5-year average PS is 84.94. The thresholds are as follows: Strongly Undervalued below -91.95, Undervalued between -91.95 and -3.51, Fairly Valued between 173.39 and -3.51, Overvalued between 173.39 and 261.83, and Strongly Overvalued above 261.83. The current Forward PS of 11.13 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Lyra Therapeutics Inc. (LYRA) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.66. The thresholds are as follows: Strongly Undervalued below -8.87, Undervalued between -8.87 and -5.27, Fairly Valued between 1.94 and -5.27, Overvalued between 1.94 and 5.55, and Strongly Overvalued above 5.55. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.21
P/FCF
Lyra Therapeutics Inc. (LYRA) has a current P/FCF of -0.21. The 5-year average P/FCF is -1.96. The thresholds are as follows: Strongly Undervalued below -4.88, Undervalued between -4.88 and -3.42, Fairly Valued between -0.50 and -3.42, Overvalued between -0.50 and 0.95, and Strongly Overvalued above 0.95. The current Forward P/FCF of -0.21 falls within the Overvalued range.
Lyra Therapeutics Inc (LYRA) has a current Price-to-Book (P/B) ratio of 2.25. Compared to its 3-year average P/B ratio of 1.59 , the current P/B ratio is approximately 41.00% higher. Relative to its 5-year average P/B ratio of 1.74, the current P/B ratio is about 28.95% higher. Lyra Therapeutics Inc (LYRA) has a Forward Free Cash Flow (FCF) yield of approximately -528.40%. Compared to its 3-year average FCF yield of -254.18%, the current FCF yield is approximately 107.88% lower. Relative to its 5-year average FCF yield of -161.22% , the current FCF yield is about 227.75% lower.
2.27
P/B
Median3y
1.59
Median5y
1.74
-530.78
FCF Yield
Median3y
-254.18
Median5y
-161.22
Competitors Valuation Multiple
The average P/S ratio for LYRA's competitors is 13.67, providing a benchmark for relative valuation. Lyra Therapeutics Inc Corp (LYRA) exhibits a P/S ratio of 11.13, which is -18.54% above the industry average. Given its robust revenue growth of -69.40%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of LYRA decreased by 58.04% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.07 to -0.11.
The secondary factor is the Margin Expansion, contributed -49.51%to the performance.
Overall, the performance of LYRA in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
JBDI
JBDI Holdings Ltd
1.000
USD
0.00%
SSKN
Strata Skin Sciences Inc
1.810
USD
0.00%
TXMD
TherapeuticsMD Inc
1.105
USD
0.00%
HWH
HWH International Inc
1.640
USD
+2.50%
AEON
Aeon Biopharma Inc
0.719
USD
+4.35%
CNFR
Conifer Holdings Inc
0.865
USD
+8.13%
HTOO
Fusion Fuel Green PLC
4.530
USD
+2.72%
YYAI
Connexa Sports Technologies Inc
4.200
USD
0.00%
CISO
CISO Global Inc
0.878
USD
0.00%
LEDS
SemiLEDs Corp
1.725
USD
0.00%
FAQ
Is Lyra Therapeutics Inc (LYRA) currently overvalued or undervalued?
Lyra Therapeutics Inc (LYRA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 11.18 is considered Undervalued compared with the five-year average of -2.47. The fair price of Lyra Therapeutics Inc (LYRA) is between 7.31 to 29.31 according to relative valuation methord. Compared to the current price of 6.60 USD , Lyra Therapeutics Inc is Undervalued By 9.74% .
What is Lyra Therapeutics Inc (LYRA) fair value?
How does LYRA's valuation metrics compare to the industry average?
What is the current P/B ratio for Lyra Therapeutics Inc (LYRA) as of Aug 13 2025?
What is the current FCF Yield for Lyra Therapeutics Inc (LYRA) as of Aug 13 2025?
What is the current Forward P/E ratio for Lyra Therapeutics Inc (LYRA) as of Aug 13 2025?